BR112022020555A2 - Anticorpo anti-cd47 e usos do mesmo - Google Patents
Anticorpo anti-cd47 e usos do mesmoInfo
- Publication number
- BR112022020555A2 BR112022020555A2 BR112022020555A BR112022020555A BR112022020555A2 BR 112022020555 A2 BR112022020555 A2 BR 112022020555A2 BR 112022020555 A BR112022020555 A BR 112022020555A BR 112022020555 A BR112022020555 A BR 112022020555A BR 112022020555 A2 BR112022020555 A2 BR 112022020555A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- same
- antigen
- treating
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
ANTICORPO ANTI-CD47 E USOS DO MESMO. A presente invenção provê um anticorpo anti-CD47 ou o fragmento de ligação ao antígeno do mesmo, um método de preparação do mesmo e o uso para tratar ou prevenir doenças relacionadas ao CD47.1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010282924 | 2020-04-10 | ||
PCT/CN2021/086339 WO2021204281A1 (en) | 2020-04-10 | 2021-04-11 | Anti-cd47 antibody and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020555A2 true BR112022020555A2 (pt) | 2022-12-06 |
Family
ID=78024001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020555A BR112022020555A2 (pt) | 2020-04-10 | 2021-04-11 | Anticorpo anti-cd47 e usos do mesmo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230151110A1 (pt) |
EP (1) | EP4132976A4 (pt) |
JP (1) | JP2023521790A (pt) |
KR (1) | KR20230015331A (pt) |
CN (1) | CN115698066A (pt) |
AR (1) | AR121805A1 (pt) |
AU (1) | AU2021251989A1 (pt) |
BR (1) | BR112022020555A2 (pt) |
CA (1) | CA3179373A1 (pt) |
CL (1) | CL2022002727A1 (pt) |
IL (1) | IL297171A (pt) |
MX (1) | MX2022012588A (pt) |
PE (1) | PE20230765A1 (pt) |
TW (1) | TW202140565A (pt) |
WO (1) | WO2021204281A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR127273A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016326423A1 (en) * | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
CN107955071B (zh) * | 2016-10-18 | 2021-03-26 | 上海赛远生物科技有限公司 | 人源抗人cd47抗体及其编码基因与应用 |
CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
CN110066336B (zh) * | 2019-05-12 | 2021-11-09 | 杭州科兴生物科技有限公司 | 抗cd47单克隆抗体、片段及其医药用途 |
AR127270A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Formulación de anticuerpos anti-cd47 |
AR127271A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |
AR127273A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |
-
2021
- 2021-04-09 TW TW110112951A patent/TW202140565A/zh unknown
- 2021-04-09 AR ARP210100941A patent/AR121805A1/es unknown
- 2021-04-11 AU AU2021251989A patent/AU2021251989A1/en active Pending
- 2021-04-11 EP EP21784434.9A patent/EP4132976A4/en active Pending
- 2021-04-11 KR KR1020227038980A patent/KR20230015331A/ko unknown
- 2021-04-11 BR BR112022020555A patent/BR112022020555A2/pt unknown
- 2021-04-11 MX MX2022012588A patent/MX2022012588A/es unknown
- 2021-04-11 JP JP2022561627A patent/JP2023521790A/ja active Pending
- 2021-04-11 US US17/995,810 patent/US20230151110A1/en active Pending
- 2021-04-11 IL IL297171A patent/IL297171A/en unknown
- 2021-04-11 CA CA3179373A patent/CA3179373A1/en active Pending
- 2021-04-11 WO PCT/CN2021/086339 patent/WO2021204281A1/en active Application Filing
- 2021-04-11 PE PE2022002149A patent/PE20230765A1/es unknown
- 2021-04-11 CN CN202180024295.4A patent/CN115698066A/zh active Pending
-
2022
- 2022-10-04 CL CL2022002727A patent/CL2022002727A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4132976A4 (en) | 2024-05-01 |
WO2021204281A1 (en) | 2021-10-14 |
CA3179373A1 (en) | 2021-10-14 |
AR121805A1 (es) | 2022-07-13 |
EP4132976A1 (en) | 2023-02-15 |
CL2022002727A1 (es) | 2023-05-26 |
KR20230015331A (ko) | 2023-01-31 |
IL297171A (en) | 2022-12-01 |
TW202140565A (zh) | 2021-11-01 |
PE20230765A1 (es) | 2023-05-09 |
AU2021251989A1 (en) | 2022-11-17 |
CN115698066A (zh) | 2023-02-03 |
US20230151110A1 (en) | 2023-05-18 |
JP2023521790A (ja) | 2023-05-25 |
MX2022012588A (es) | 2022-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
DOP2020000245A (es) | Anticuerpos il-11 | |
BR112018016226A8 (pt) | Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica | |
BR112019002282A2 (pt) | anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas | |
WO2020082209A8 (zh) | 抗cldn18.2抗体及其用途 | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
CL2020002103A1 (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139) | |
UY37591A (es) | Conjugados de fármaco anticuerpo | |
BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
BR112022020555A2 (pt) | Anticorpo anti-cd47 e usos do mesmo | |
CO2019002608A2 (es) | Biomarcadores de arn para angioedema hereditario | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
CO2023018064A2 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
CO2020012638A2 (es) | Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos | |
BR112018068637A2 (pt) | podocalixina e anticorpo relacionado a tra, métodos de preparação e usos como agente terapêutico anticancerígeno | |
BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
BR112022026922A2 (pt) | Anticorpo anti-lilrb1 e usos do mesmo |